Dichloropane
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Dichloropane (RTI-111, O-401) is a synthetic stimulant of the phenyltropane class. It is a structural analog of cocaine with substantially greater potency at monoamine transporters. Dichloropane is a serotonin–norepinephrine–dopamine reuptake inhibitor, producing its effects by blocking the recycling of dopamine, serotonin, and norepinephrine from the synapse.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, dopamine reuptake inhibitors, stimulants +1 morecocaine, dopamine reuptake inhibitors, stimulants, phenyltropanes show less
Synthesized in 1993 by Meltzer and colleagues at Massachusetts General Hospital, dichloropane was described as "one of the most potent cocaine congeners yet reported".[2] It was studied within RTI International's phenyltropane program as a potential cocaine addiction pharmacotherapy but was not advanced to clinical development.[3] The compound appeared on the research chemical market around 2010 and prompted an EMCDDA early warning notification in 2016.[4]
Subjective effects include euphoria, stimulation, focus enhancement, and mood elevation. The experience is reported as a sustained, moderate-onset stimulation with possible affective warmth from the compound's unusually strong serotonergic component — somewhere between cocaine and entactogenic stimulants. Anxiety, sympathetic hyperarousal, and post-use dysphoria are characteristic unsought effects.
Dichloropane is considered moderately addictive; no toxicity data, lethal dose, or therapeutic index have been established.safety citation needed The phenyltropane class shows lower reinforcing strength than cocaine due to slower transporter occupancy onset,[5][6][7] but cardiovascular stress persists longer than with cocaine and compounds risk during extended use. No controlled human studies exist; the entire understanding rests on animal pharmacology, structural analogy, and limited forensic cases.
History[edit]
Discovery
Dichloropane was first synthesized in 1993 by Peter C. Meltzer and colleagues at Massachusetts General Hospital and Harvard Medical School.[2] The compound emerged from a systematic program evaluating substituted phenyltropane analogs as inhibitors of cocaine binding, and was described as "one of the most potent cocaine congeners yet reported".[2] It was subsequently incorporated into Research Triangle Institute's phenyltropane program, where it received the designation RTI-111.[3]
Preclinical development
The RTI phenyltropane program synthesized hundreds of cocaine analogs seeking a long-acting, low-abuse-potential pharmacotherapy for cocaine addiction — conceptually analogous to methadone for opioid dependence. Dichloropane was evaluated in self-administration and discriminative stimulus paradigms in primates[8] and rats,[9] and was tested as a PET imaging probe for dopamine terminals.[10] Despite its potency, it was not selected for clinical advancement; RTI-336 proceeded as the program's lead candidate.[3]
Research chemical market
Dichloropane appeared on the online research chemical market around 2010, reportedly among the earliest cocaine analogs available in this context.[4] Forensic seizures in Sweden and Slovenia prompted a formal EMCDDA early warning notification (EU-EWS-RCS-FN-2016 0065) in late 2016.[4] Three human forensic cases were documented by the University of Freiburg, with blood concentrations of approximately 1.0 ng/mL.[11]
The alternative designation O-401 appears in regulatory filings.[12] Beyond direct pharmacological investigation, the dichloropane scaffold has served as the parent structure for fluorescent DAT probes — notably JHC 1-64, a rhodamine-labeled analog used to visualize transporter trafficking in live neurons.[13][14][15]
Chemistry[edit]
Structural class
Dichloropane belongs to the phenyltropane family, a class of synthetic tropane derivatives designed as structural analogs of cocaine. The parent scaffold replaces cocaine's benzoyl ester with a direct aryl–carbon bond at the 3β position while retaining a methyl ester at 2β. Dichloropane is distinguished by 3,4-dichloro substitution on the phenyl ring, which increases lipophilicity and strengthens transporter binding through enhanced hydrophobic interactions.[16]
Molecular identity
A structural identity ambiguity exists for this compound. Two distinct molecules are marketed as "dichloropane" or "RTI-111": (1) the nortropane (secondary amine, CAS 146725-34-0, MW 314.2), confirmed by PubChem and NCATS;[1] and (2) the N-methyl tropane salt (tertiary amine, CAS 150653-91-1, MW 364.7), sold by some chemical vendors.[17] PsychonautWiki lists an IUPAC name corresponding to the N-methyl form,[4] contradicting the PubChem/NCATS assignment. This article follows the PubChem/NCATS canonical assignment (nortropane), consistent with the enhanced transporter affinity expected from N-demethylation.[18]| Molecular formula | C₁₅H₁₇Cl₂NO₂ |
| Molecular weight | 314.2 g/mol |
The molecule consists of a nortropane ring system with a methyl ester at the 2β position and a 3,4-dichlorophenyl group at the 3β position.[1] It is part of the RTI series, which includes troparil, RTI-112, and RTI-336.[3]
Stereochemistry
Dichloropane possesses four chirality centers at positions 1R, 2S, 3S, and 5S of the tropane ring.[1] This absolute configuration — the β-series — corresponds to the biologically active stereochemistry for DAT binding, matching the natural cocaine stereochemistry. Structure–activity studies confirm that the (R)-2β-substituted 3β-(3,4-dichlorophenyl)tropane scaffold occupies the high-affinity binding range at DAT.[19]
Physical properties
| Appearance | White powder |
| Boiling point (predicted) | 407.6 ± 45.0 °C |
| pKa (predicted) | 9.70 |
All physical property values are computationally predicted; no experimentally determined data have been published.[20] The predicted pKa indicates the secondary amine is predominantly protonated at physiological pH.
Pharmacology[edit]
Mechanism of action
Dichloropane acts as a potent serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), blocking all three major monoamine transporters simultaneously.[1] By preventing dopamine, serotonin, and norepinephrine from being cleared from the synapse, it increases the concentration and signaling duration of all three neurotransmitters. The inhibition profile is nonselective, with strongest binding at the DAT and substantial activity at the serotonin and norepinephrine transporters.[2]
The nortropane structure is pharmacologically significant: removing the N-methyl group found in many phenyltropanes markedly enhances serotonin and norepinephrine transporter affinity with minimal change at the dopamine transporter.[18] This produces a more balanced monoamine profile than DAT-selective cocaine analogs.
Unlike Cocaine, dichloropane does not block voltage-gated sodium channels and therefore lacks local anesthetic activity.[4]
Pharmacokinetics
No human pharmacokinetic studies have been published for dichloropane. Bioavailability, peak plasma time, half-life, and protein binding remain uncharacterized in any species.
In animal studies, dichloropane shows slower brain uptake and longer duration of action compared to cocaine,[4] consistent with higher transporter binding affinity creating prolonged occupancy. PET imaging in primates confirmed binding in both dopamine-rich striatal regions and serotonin-rich thalamic regions.[10]
No published data on metabolic pathways exist. By structural analogy with cocaine-class compounds, the primary route is presumed to be ester hydrolysis by plasma and liver enzymes.inferred Forensic casework detected the ester hydrolysis metabolite in human specimens at blood concentrations of approximately 1.0 ng/mL.[11]
Neuroscience[edit]
Where it acts
Dichloropane potentiates monoamine signaling across three major brain systems. Dopamine reuptake inhibitor in the mesolimbic pathway — from the ventral tegmental area to the nucleus accumbens — drives reinforcement and euphoria. The compound functions as a positive reinforcer in primate self-administration[8] and produces cocaine-like discriminative stimulus effects in rats,[9] confirming engagement of this reward circuit.
The substantial SERT component distinguishes dichloropane from DAT-selective stimulants. PET imaging confirmed accumulation in serotonin-rich thalamic regions,[10][21] suggesting serotonergic modulation that may introduce affective warmth absent from purely dopaminergic stimulants. Norepinephrine transporter blockade drives arousal, elevated heart rate, and pupil dilation.
Why it matters
The rate of dopamine transporter occupancy is a critical determinant of a stimulant's reward signal. Rapid dopamine surges in the nucleus accumbens produce stronger reinforcement; slower, sustained increases produce weaker reward responses.[5][7] Dichloropane's slower onset compared to cocaine may generate a qualitatively different reward signal — potentially reducing compulsive pursuit while maintaining subjective effects.
The phenyltropane series showed an absence of behavioral sensitization in some animal models,[3] and the framework distinguishing "typical" from "atypical" dopamine transporter ligands[22] places dichloropane in an ambiguous position — slower onset and balanced transporter binding suggest it may not fit neatly into either category.
Key unresolved questions include whether dichloropane's balanced transporter inhibition produces qualitatively different subjective effects than DAT-selective stimulants, whether its serotonergic component confers entactogen-adjacent properties, and whether the slower onset translates to reduced abuse liability in humans as predicted by primate models. The pharmacokinetic basis for the reported 2–4 hour insufflated duration — whether driven by slow absorption, tissue binding, or prolonged receptor association — also remains unknown.
Subjective Effects[edit]
No controlled human studies have characterized dichloropane's subjective experience. Based on its pharmacological profile and limited community reports, the compound produces a sustained stimulant state with moderate onset — distinct from cocaine's rapid, compressed rush. The unusually potent SERT engagement may introduce an affective warmth or emotional openness not typical of DAT-selective stimulants, shifting the experience toward entactogen-adjacent territory at some doses. Route of administration substantially modulates the character of the experience: smoked delivery compresses the profile into a brief, intense window, while insufflation yields a more gradual and extended course.
Relative to Cocaine, dichloropane occupies an unusual pharmacological niche — a reuptake inhibitor rather than a releasing agent, with stronger serotonergic character than most commonly encountered stimulants. The closest experiential comparators may be other nonselective reuptake inhibitors, though few are widely available for comparison.
Effect Grid
Pronounced stimulation and clear cognitive euphoria define the experience. Focus enhancement and thought acceleration are significant — sustained attention and motivation enhancement are readily apparent. The serotonergic component may produce an affective warmth or subtle entactogen-adjacent quality alongside conventional stimulant effects. Disinhibition and sociability enhancement are noticeable.
Cardiovascular effects become notable: elevated heart rate, vasoconstriction, and possible abnormal heartbeat. Appetite suppression is clear. Bruxism and excessive sweating may emerge. Wakefulness is sustained throughout the experience, with a dehydration sensation prompting fluid intake.
Insufflated duration spans 2–4 hours total, while smoked effects compress into 40–75 minutes. Compulsive redosing urge may emerge, particularly via the smoked route. Sleep will be disrupted for several hours post-dose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Touch enhancement · Tinnitus
Pupil dilation · Body high · Dry mouth · Heart rate perception changes · Insomnia · Muscle tension · Physical fatigue · Restlessness · Respiratory stimulation · Excessive sweating · Dehydration sensation · Breathing alteration · Bruxism · Bodily lightness · Headache · Tactile euphoria · Sexual arousal enhancement · Abnormal heartbeat · Pain suppression · Sexual arousal suppression · Dizziness · Nasal congestion · Nausea · Tingling / electric sensations · Trembling · Brain zaps
Heart rate perception changes · Insomnia · Muscle tension · Physical fatigue · Restlessness · Respiratory stimulation · Excessive sweating · Dehydration sensation · Breathing alteration · Bruxism · Bodily lightness · Headache · Tactile euphoria · Sexual arousal enhancement · Pain suppression · Sexual arousal suppression · Dizziness · Nasal congestion · Nausea · Tingling / electric sensations · Trembling · Brain zaps
Motivation enhancement · Focus enhancement · Motivation suppression · Information processing enhancement · Analysis enhancement · Language enhancement · Thought organization · Cognitive dysphoria · Pattern recognition enhancement · Thought loops · Creativity enhancement · Memory enhancement · Thought deceleration · Aesthetic enhancement · Thought disorganization
Analysis enhancement · Language enhancement · Thought organization · Cognitive dysphoria · Pattern recognition enhancement · Thought loops · Creativity enhancement · Memory enhancement · Thought deceleration · Aesthetic enhancement · Thought disorganization
Anhedonia · Dysphoria · Mania
Communication enhancement · Sociability enhancement · Social connection · Flow state
Timeline
Gradual emergence of stimulation over 15-30 minutes as dichloropane absorbs through nasal mucosa. Subtle alertness increase and mild heart rate elevation are the first perceptible signs.
Progressive intensification of stimulant effects. Focus enhancement, thought acceleration, and appetite suppression become clearly apparent. Cardiovascular activation builds steadily.
Full stimulation with cognitive euphoria, sustained focus, and motivation enhancement. Cardiovascular effects are prominent. The serotonergic component may contribute subtle mood warmth beyond conventional stimulant affect.
Gradual decline over 60-90 minutes. Residual wakefulness and appetite suppression persist. Irritability, dysphoria, and mild depression may emerge as monoamine levels normalize.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 9 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- cocaine · dopamine reuptake inhibitors · stimulants
Toxicity
No controlled toxicity data, lethal dose values, or organ-specific toxicity studies have been published for dichloropane.safety citation needed All assessments below are inferred from the compound's pharmacological class and should be treated as provisional.
Cardiovascular toxicity
Dichloropane is expected to produce dose-dependent cardiovascular stress — elevated heart rate, raised blood pressure, and vasoconstriction — through increased dopamine and norepinephrine signaling.[1] Because its duration exceeds cocaine's, this cardiovascular strain persists longer per dose.
Unlike cocaine, dichloropane does not block sodium channels,[4] which may reduce the risk of certain heart rhythm disturbances. However, catecholamine-driven vessel spasm, reduced blood flow to the heart, and stress-related heart muscle damage remain class-level risks.
Overheating risk
Simultaneous dopamine and serotonin reuptake inhibitor increases the risk of dangerous overheating, particularly in hot environments or during physical exertion.inferred This is a documented class effect of dual DAT/SERT inhibitors.
Seizure risk
Potent stimulants lower the seizure threshold in a dose-dependent manner. No seizure data specific to dichloropane have been published.safety citation needed
Forensic case data
Three human forensic cases positive for dichloropane were documented in a conference poster, with blood concentrations of approximately 1.0 ng/mL and urine concentrations of approximately 4.5 ng/mL.[11] No fatalities directly attributable to dichloropane were identified in the available literature.
Psychological risks
No controlled human studies have assessed dichloropane's psychological risk profile. As a stimulant-class SNDRI, the following risks are anticipated:
- Stimulant psychosis: High-dose or prolonged use can trigger paranoia, agitation, and psychotic symptoms from excessive dopamine activity.inferred
- Anxiety and panic: Norepinephrine-driven arousal at higher doses may produce acute anxiety, panic attacks, and physical hyperarousal.
- Post-use crash: Monoamine depletion after sustained reuptake inhibition can produce rebound effect low mood, anhedonia, and depressive symptoms — particularly after binge use.
- Compulsive redosing: Dichloropane functions as a positive reinforcer in primate models,[8] indicating liability for compulsive use, though slower onset may partially reduce this risk compared to cocaine.[23]
Tolerance and dependence
No substance-specific tolerance or dependence studies have been published.safety citation needed Current tolerance estimates (half-life, reset period, cross-tolerances) are class-level approximations, not sourced from dichloropane research.
Tolerance to cocaine-class compounds develops through downregulation and transporter upregulation in the dopamine system. The phenyltropane series showed an absence of behavioral sensitization in some animal models,[3] which may indicate a different tolerance trajectory than cocaine — though this has not been confirmed for dichloropane specifically.
The strong serotonin transporter component introduces an additional dimension: prolonged serotonin reuptake inhibition can produce serotonin system desensitization, with potential mood and anxiety disturbances upon cessation — mechanistically similar to antidepressant discontinuation effects.
Dependence liability is class-inferred, not substance-specific.safety citation needed The phenyltropane class generally shows lower reinforcing strength than cocaine, attributed to slower onset of transporter occupancy.[5][6][7] However, dichloropane functions as a positive reinforcer in primate models and produces cocaine-like discriminative stimulus effects,[8][9] confirming real abuse potential. Non-DAT-selective analogs may carry lower abuse potential than DAT-selective compounds, though this relationship is complex.[23]
Drug interactions
No published interaction studies specific to dichloropane exist. All assessments are inferred from its SNDRI mechanism.safety citation needed
Serotonergic drugs: Combining dichloropane with MAOIs (phenelzine, tranylcypromine, or selegiline at high doses) risks serotonin syndrome — a potentially fatal accumulation of serotonin from combined reuptake inhibition and breakdown prevention. SSRIs and SNRIs produce additive serotonin reuptake inhibition with elevated risk.
Other stimulants: Combination with amphetamines, methylphenidate, cathinones, or cocaine compounds cardiovascular strain through additive dopamine and norepinephrine effects. Cocaine additionally introduces sodium channel blockade absent from dichloropane alone.
Alcohol and depressants: CNS depressants may mask stimulant-related impairment, creating a false sense of sobriety while cardiovascular stress continues unabated.
Blood pressure medications: Stimulant-induced sympathetic activation may reduce the effectiveness of blood pressure medications through opposing mechanisms.
Contraindications
No substance-specific contraindication data exist.safety citation needed
Absolute (class-inferred):
- Concurrent MAOI use: Risk of serotonin syndrome — potentially fatal
- Serious heart conditions: Including uncontrolled high blood pressure, recent heart attack, heart failure, or significant rhythm disturbances
- Pheochromocytoma: Catecholamine-potentiating compounds risk dangerous blood pressure spikes
Relative (class-inferred):
- Seizure disorders: Stimulants lower the seizure threshold
- Anxiety disorders and psychotic conditions: Norepinephrine and dopamine potentiation may worsen symptoms
- Overactive thyroid: Additive stimulant effects with existing catecholamine excess
- Concurrent serotonergic medication: SSRIs, SNRIs, triptans, tramadol — elevated serotonin syndrome risk
- Pregnancy and lactation: No reproductive safety data exist; stimulant-class compounds are generally contraindicatedinferred
Harm Reduction[edit]
Forms & Identification
Dichloropane typically circulates as a white powder, visually indistinguishable from many other stimulant research chemicals. The structural identity ambiguity between the nortropane and N-methyl tropane forms means material sold as "RTI-111" or "dichloropane" may contain either molecular entity — or neither. Reagent testing can confirm the presence of a tropane-class compound but cannot reliably distinguish between the two structural variants or verify purity.
Given the absence of established dose–response data in humans, treating any batch as potentially more potent than expected is prudent.
Guidelines
- Test every batch with reagent kits before use
- Start with the lowest plausible dose and wait the full onset period before considering redosing — insufflation onset can take 15–30 minutes
- Keep water accessible and drink regularly to offset dehydration and overheating risk
- Avoid hot, crowded environments where overheating risk is highest
- Do not use alone — have a sober companion present, especially with an unfamiliar batch
- Set a hard stop time; stimulant sessions that extend through the night carry compounding cardiovascular and psychological risk
- Eat a meal beforehand — stimulants suppress appetite, and low blood sugar worsens physical stress
Set & Setting
A calm, familiar environment with trusted company reduces the likelihood of anxiety escalation. Stimulant experiences amplify existing mental states — entering a session anxious, agitated, or sleep-deprived increases the risk of panic and compulsive redosing. Plan the session duration in advance and set a firm boundary on redosing before the first dose.
Aftercare & integration. The post-stimulant crash following dichloropane use may include low mood, fatigue, irritability, and difficulty concentrating as monoamine systems recover. Prioritize sleep — use blackout curtains and avoid screens if the session extended into nighttime hours.
Eat nutrient-dense meals, particularly foods rich in protein and complex carbohydrates, to support neurotransmitter precursor replenishment. Avoid redosing to "fix" the comedown; this pattern extends recovery time and increases dependence risk. If low mood persists beyond 48–72 hours, or if cravings feel difficult to manage, consider speaking with a healthcare provider.
Recovery & Support
Compulsive stimulant use can develop gradually, particularly when use shifts from planned sessions to spontaneous redosing or daily patterns. Warning signs include increasing dose frequency, neglecting responsibilities during or after use, and difficulty maintaining planned abstinence periods.
Support resources include SAMHSA's National Helpline (1-800-662-4357), free, confidential, and available 24/7. Cognitive behavioral therapy has the strongest evidence base for stimulant use disorders. Peer support through groups such as SMART Recovery offers non-12-step alternatives for those who prefer structured self-management approaches.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, or body temperature hot enough to feel through clothing are immediate red flags. Severe agitation, paranoid delusions, or self-harm behavior also require emergency intervention.
Immediate steps:
- 1. Call emergency services immediately if any red flag is present
- 2. Move the person to a cool, quiet space
- 3. Remove excess clothing to aid cooling
- 4. If unconscious but breathing, place in the recovery position (on their side, airway clear)
- 5. Do not restrain unless there is immediate danger of self-harm
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (dichloropane / RTI-111), the amount taken if known, the time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for stimulant overdose. Medical treatment is supportive — cooling, sedation, and cardiovascular monitoring.
Legal Status[edit]
As of May 2026, dichloropane is not specifically scheduled under most national drug control frameworks but falls within the scope of structural analog and psychoactive substance legislation in several jurisdictions. Its status as a structural analog of cocaine (Schedule II in the United States) subjects it to broad analog provisions where such legislation exists.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not explicitly scheduled | Subject to the Federal Analogue Act (21 U.S.C. § 813) as a structural analog of cocaine (Schedule II); prosecution requires evidence of intent for human consumption |
| United States (Vermont) | Explicitly regulated | Listed in Vermont Code of Regulations 13-140-011-X as "Dichloropane; RTI-111; 0-401";[12] misclassified under "Hallucinogenic Drugs" category |
| United Kingdom | Covered under Psychoactive Substances Act 2016 | Blanket ban on psychoactive substances not otherwise exempted; no specific scheduling under the Misuse of Drugs Act 1971 |
| European Union | EMCDDA early warning issued (2016) | Formal notification EU-EWS-RCS-FN-2016 0065 following forensic seizures in Sweden and Slovenia;[4] no EU-wide scheduling confirmed; member state legislation varies |
| Sweden | Likely controlled | Site of first forensic seizure (late 2016); national NPS legislation likely applies |
| Slovenia | Likely controlled | Second 2016 seizure sample; national NPS legislation likely applies |
| Canada | Not explicitly named | Not listed in the Controlled Drugs and Substances Act; may fall under analogue provisions |
| Australia | Unclear | Not found in the national Poisons Standard; state and commonwealth psychoactive substance amendments may apply |
Analog and classification considerations
The Federal Analogue Act (21 U.S.C. § 813) treats any substance "substantially similar" in chemical structure or pharmacological effect to a Schedule I or II controlled substance as controlled when intended for human consumption. As a direct structural analog of cocaine sharing the same mechanism of action, dichloropane falls within this provision's scope.
Vermont's classification of dichloropane under "Hallucinogenic Drugs; synthetic Cannabinoids; Tryptamines; Cannabimimetics; mescaline Analogs; Dissociatives" is a pharmacological misclassification.[12] Dichloropane has no hallucinogenic, cannabimimetic, or dissociative mechanism. The placement likely reflects administrative convenience rather than pharmacological assessment.
references
- [1]
- [2] ^abcdMeltzer PC, Liang AY, Brownell AL, Elmaleh DR, Madras BK (1993) Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging — Journal of Medicinal Chemistry PMID:8464040
- [3]
- [4]
- [5] ^abcWee S, Carroll FI, Woolverton WL (2006) A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants — Neuropsychopharmacology doi:10.1038/sj.npp.1300795
- [6] ^abCzoty PW, Martelle JL, Carroll FI, Nader MA (2010) Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates — Pharmacology, Biochemistry and Behavior doi:10.1016/j.pbb.2010.05.017